Clinical Trials in Gleizé, France
5 recruiting
Showing 1–8 of 8 trials
Recruiting
Not Applicable
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
ALK+ Non-Small-Cell Lung Carcinoma
Pfizer90 enrolled31 locationsNCT06487078
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Not Applicable
Feasibility Study of a Patient-centered CDS for Recommended Screenings in Primary Care
Primary Care
Hospices Civils de Lyon210 enrolled20 locationsNCT07270926
Recruiting
REBECCA Real-world Early BrEast CanCer mAnagement
Breast Cancer
AstraZeneca126 enrolled58 locationsNCT06856343
Recruiting
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Genetic DiseaseAutoimmune DiseasesNeurological Diseases or Conditions+1 more
Imagine Institute500 enrolled32 locationsNCT07040774
Recruiting
Not Applicable
Diagnostic Efficacy of Connected WAtch ECG Versus External Holter ECG
Heart Disease
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône81 enrolled1 locationNCT06420960
Recruiting
Phase 2
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Gastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaEsophagus Adenocarcinoma
UNICANCER118 enrolled29 locationsNCT05476796